All studies
RecruitingTherapeutic confirmatory (Phase III)Interventional

Prospective, randomized, non-treatment controlled, investigator-blinded, multicenter study on the prophylaxis of early childhood symptoms of atopic dermatitis in high-risk children by continuous continuous application of a moisturizing barrier-stabilizing skin cream

Atopic eczema is a very common skin condition that causes dry, red, and itchy skin. It often starts in early infancy, especially in babies with a family history of allergies. This clinical trial is testing whether a barrier-strengthening moisturiser called SanaCutan® Basiscreme can stop eczema from developing in high-risk babies. Babies joining the study are placed by chance into one of two groups. One group has the moisturising cream applied regularly to their skin, while the other group receives standard routine care without the trial cream. Doctors will check each baby's skin regularly over their first year of life. They will look for early signs of dryness, itching, and eczema patches, and also check for common childhood allergies. The aim is to see if protecting the skin barrier early in life can prevent long-term eczema.

At a glance

Status
Recruiting
Phase
Therapeutic confirmatory (Phase III)
Sponsor
INFECTOPHARM Arzneimittel und Consilium GmbH
Enrolment target
360
Start
17 Oct 2024

What is this study about?

Atopic dermatitis, commonly known as atopic eczema, causes patches of dry, irritated, and intensely itchy skin. It often begins in the first few months of life and can cause sleep loss and distress for both babies and parents. Research suggests that eczema may start because the skin's natural protective outer layer—the skin barrier—is fragile, allowing moisture to escape and irritants to enter.

This study explores whether protecting a baby's skin barrier from the very beginning can stop eczema from developing at all. SanaCutan® Basiscreme is a gentle, hydrating cream designed to support and strengthen the skin barrier. Doctors want to see if applying this cream daily to babies who have a higher chance of developing eczema can prevent the condition before symptoms become chronic.

Taking part in this study helps researchers answer an important question about early infant care. If a simple, daily moisturising routine can stop eczema from starting, it could spare many children from years of uncomfortable skin symptoms and might also reduce the chance of developing related allergic conditions.

Key takeaways

  • Tests whether a daily moisturising cream can prevent eczema in babies at high risk.
  • Follows babies through planned clinic check-ups up to 12 months of age.
  • Babies are randomly placed into either the daily cream group or a standard care group.
  • Monitors skin dryness, itchiness, eczema flare-ups, and common allergies.
  • Participation is entirely voluntary, and you can stop at any time.

Who may be eligible?

This trial is designed for newborn babies and young infants who are considered to have a high risk of developing atopic eczema. A baby is usually considered high risk if one or both parents, or a brother or sister, has a history of eczema, asthma, or hay fever.

Babies of any gender can take part. However, if a baby already has severe, established eczema or other serious skin disorders before starting, this study may not be suitable for them.

Because the study tracks babies through their first year of life, parents or carers must be able to attend regular check-ups and follow the study instructions for skin care. The study doctor will review your family's medical history to confirm whether your baby is eligible.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Your baby is a newborn or young infant.
  2. There is a family history of eczema, asthma, or hay fever in parents or siblings.
  3. Your baby does not already have severe, established eczema.
  4. You are willing to apply cream daily if assigned to that group.
  5. You are able to attend clinic visits over your baby's first year.
Answer every question to see your result.

What does participation involve?

If you decide to take part, your baby will be followed for up to 12 months. Your baby will be placed into a group by chance (like flipping a coin). One group will apply SanaCutan® Basiscreme regularly to the baby's skin, while the other group will follow normal infant skin care without the study cream.

You will bring your baby to clinic visits at planned ages, including around 12 weeks, 16 weeks, 6 months, 9 months, and 12 months. During these visits, doctors will gently examine your baby's skin for dryness, redness, or signs of itching. The team will also perform standard checks for allergies, which may include simple blood or skin tests. You will be asked to keep a brief record of the creams you use and any changes you notice in your baby's skin.

Potential risks and benefits

Your baby will receive close, expert skin monitoring throughout their first year, and using the cream may help keep their skin comfortable and well-hydrated. However, there is no guarantee that taking part will prevent eczema. As with any skin cream, there is a small chance of mild skin irritation, redness, or a rash. Routine allergy checks may also cause brief fussiness or minor discomfort. Taking part is completely voluntary, and you can withdraw your baby from the study at any time without giving a reason and without affecting your regular NHS healthcare.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

What does 'high risk' of eczema mean?

It usually means that eczema, asthma, or allergic rhinitis (hay fever) runs in your baby's close family, such as in a parent or sibling.

Will my baby definitely get the study cream?

Not necessarily. Babies are randomly assigned to either the group using the study cream or a comparison group receiving standard care.

Is SanaCutan® Basiscreme a steroid cream?

No. It is a non-steroid, barrier-stabilising moisturising cream designed to keep the skin hydrated and protected.

What happens if my baby develops eczema during the trial?

The study doctors will examine your baby's skin and ensure they receive appropriate standard medical treatment to keep them comfortable.

Can I leave the study if it becomes too difficult to attend visits?

Yes. You are free to leave the trial at any point, and your baby's everyday medical care will continue as normal.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Prospective, randomized, non-treatment controlled, investiga…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.